中国肾移植术后并发恶性肿瘤趋势分析

王超; 李涛; 张健; 刘芬; 解泽林; 唐雅望; 孙雯; 郭洪波; 林俊; 张磊; 田野; 马麟麟

doi:10.3969/j.issn.1674-7445.2015.03.008

中国肾移植术后并发恶性肿瘤趋势分析

doi: 10.3969/j.issn.1674-7445.2015.03.008

100050 首都医科大学附属北京友谊医院泌尿外科(王超、张健、解泽林、唐雅望、孙雯、郭洪波、林俊、张磊、田野、马麟麟)；陕西省西安市中心医院泌尿外科(李涛)；首都医科大学流行病与卫生统计学院(刘芬)；移植耐受与器官保护北京市重点实验室(马麟麟)

基金项目:

国家自然科学基金 81372737

详细信息

通讯作者:
马麟麟, Email:malinlin1009@126.com

中图分类号: R617
计量
- 文章访问数: 121
- HTML全文浏览量: 93
- PDF下载量: 6
- 被引次数: 0
出版历程
- 收稿日期: 2015-03-12
- 网络出版日期: 2021-01-19
- 刊出日期: 2015-05-15

Trend analysis of malignant tumor after renal transplantation in China

Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

More Information

Corresponding author: Ma Linlin, Email:malinlin1009@126.com

摘要

摘要: 目的通过收集分析近10余年来我国公开报道的肾移植术后并发恶性肿瘤的流行病学及临床特征资料, 试图揭示中国肾移植术后并发恶性肿瘤的变化趋势。方法以"肾移植"和"肿瘤"为检索词, 检索中国学术期刊网络版总库和中国学术期刊数据库。严格筛选出符合标准的研究, 分析恶性肿瘤总体情况、发生部位和地域差异等。结果共筛选出2003年至2014年9篇文献及首都医科大学附属北京友谊医院单中心肾移植病例共计15 120例, 肾移植术后发生恶性肿瘤共计446例, 肿瘤发生率为2.95%(446/15 120), 移植后肿瘤以泌尿系统肿瘤(55.8%)为主。结论我国肾移植患者罹患恶性肿瘤的总发生率为2.95%, 以泌尿系肿瘤最常见。因此, 肾移植术后肿瘤筛查应作为患者随访的常规检查项目。
- 肾移植 /
- 肿瘤 /
- 发生率 /
- 变化趋势
Abstract: Objective To reveal the change trend of malignant tumor after renal transplantation in China based on the epidemiological and clinical features that were publicly reported in China in recent 10 years. Methods The search terms'renal transplantation' and'tumor'were searched on China Academic Journal Network Publishing Database and China Science Periodical Database to screen out the qualified researches strictly. General conditions, tumor sites and regional differences of malignant tumors were analyzed. Results Fifteen thousand one hundred and twenty cases from nine literatures published from 2003 to 2014 and a single-center experience of renal transplantation in Beijing Friendship Hospital of Capital Medical University were screened out. Four hundred and fourty-six cases had malignant tumor after renal transplantation with the total tumor incidence of 2.95% (446/15 120) and the tumors were mainly urinary system tumors after transplantation (55.8%). Conclusions The total incidence of malignant tumor in renal transplant recipients is 2.95% and the urinary system tumors are most common. Thus, tumor screening after renal transplantation should be taken as the routine examination during follow-up.
- Renal transplantation /
- Tumor /
- Incidence /
- Change trend

HTML全文

表 1 本研究纳入的10篇文献的基本资料

Table 1. Basic data of ten literatures in this study

文献	文献来源	文献统计年限	地域	恶性肿瘤发生率
Zhang J，et al^[4]	Med Oncol	1974～2014	北京	5.2%(179/3 462)
范昱，等^[5]	中华器官移植杂志	1978～2005	上海	3.2%(58/1 812)
郝俊文，等^[6]	中华器官移植杂志	1978～2009	山东	2.0%(39/1 945)
于立新，等^[7]	中华器官移植杂志	1978～2008	广州	1.9%(59/3 150)
相华，等^[8]	中华器官移植杂志	1991～2006	新疆	2.4%(10/424)
王海，等^[9]	癌症进展杂志	1991～2006	北京	2.8%(14/500)
徐小明，等^[10]	中华移植杂志：电子版	1983～2011	浙江	2.4%(34/1 400)
俞欣，等^[11]	南京医科大学学报	1978～2009	江苏	1.7%(15/1 292)
曹文军，等^[12]	中国当代医药	1981～2011	内蒙古	3.5%(11/310)
马永文，等^[13]	实用医技杂志	1994～2010	山西	3.3%(27/825)

下载: 导出CSV

参考文献(34)

[1]	解俊杰, 钱叶勇, 石炳毅, 等.肾移植患者术后并发原肾恶性肿瘤3例报告及文献复习[J].器官移植, 2012, 3(3):163-167. http://www.organtranspl.com/browse/detail/cat/32/id/600 Xie JJ, Qian YY, Shi BY, et al. The native kidney malignancy in post-renal transplant patients:a report of three cases and literature review[J]. Organ Transplant, 2012, 3(3):163-167. http://www.organtranspl.com/browse/detail/cat/32/id/600
[2]	牛斌, 林静, 陈晓瑜, 等.肾移植术后新发恶性肿瘤临床分析[J].器官移植, 2013, 4(2):91-94. http://www.organtranspl.com/browse/detail/cat/32/id/309 Niu B, Lin J, Chen XY, et al. Clinical analysis of de novo malignancies after renal transplantation[J]. Organ Transplant, 2013, 4(2):91-94. http://www.organtranspl.com/browse/detail/cat/32/id/309
[3]	Kapoor A.Malignancy in kidney transplant recipients[J]. Drugs, 2008, 68(Suppl 1):11-19. doi: 10.2165/00003495-200868001-00003?view=classic
[4]	Zhang J, Ma L, Xie Z, et al. Epidemiology of post-transplant malignancy in Chinese renal transplant recipients:a single-center experience and literature review[J]. Med Oncol, 2014, 31(7):32. doi: 10.1007/s12032-014-0032-6
[5]	范昱, 谈鸣岳.肾移植后恶性肿瘤58例的治疗体会[J].中华器官移植杂志, 2009, 30(1):34-36. http://d.wanfangdata.com.cn/Periodical/zhqgyz98200901008 Fan Y, Tan MY. Clinical experience in treatment of malignant tumors after kidney transplantation[J]. Chin J Organ Transplant, 2009, 30(1):34-36. http://d.wanfangdata.com.cn/Periodical/zhqgyz98200901008
[6]	郝俊文, 宋华, 常征, 等.肾移植术后恶性肿瘤39例临床分析[J].肿瘤研究与临床, 2012, 24(1):38-40. http://d.wanfangdata.com.cn/Periodical/zlyjylc201201011 Hao JW, Song H, Chang Z, et al. Clinical study of 39 patients with malignant tumor after renal transplantation[J]. Cancer Res Clin, 2012, 24(1):38-40. http://d.wanfangdata.com.cn/Periodical/zlyjylc201201011
[7]	于立新, 苗芸, 邓文锋, 等.肾移植受者新发恶性肿瘤的生存分析[J].中华器官移植杂志, 2010, 31(5):265-268. http://d.wanfangdata.com.cn/Periodical/zhqgyz98201005003 Yu LX, Miao Y, Deng WF, et al. De novo cancers in kidney transplant recipients[J]. Chin J Organ Transplant, 2010, 31(5):265-268. http://d.wanfangdata.com.cn/Periodical/zhqgyz98201005003
[8]	相华, 张辉, 荣景, 等.肾移植术后并发恶性肿瘤10例[J].中华器官移植杂志, 2007, 28(10):616. http://d.wanfangdata.com.cn/Periodical/zhqgyz98200710024 Xiang H, Zhang H, Rong J, et al. Malignant tumor after renal transplantation:a report of 10 cases[J]. Chin J Organ Transplant, 2007, 28(10):616. http://d.wanfangdata.com.cn/Periodical/zhqgyz98200710024
[9]	王海, 纪志刚, 薛翀, 等.肾移植术后恶性肿瘤:14例病例[J].癌症进展, 2009, 7(6):665-668. http://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ200906022.htm Wang H, Ji ZG, Xue C, et al. Malignancies after kidney transplantation:analysis of 14 cases[J]. Oncol Prog, 2009, 7(6):665-668. http://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ200906022.htm
[10]	徐小明, 张岩, 徐自强, 等.肾移植受者并发恶性肿瘤34例临床分析[J/CD].中华移植杂志:电子版, 2012, 6(2):97-104. Xu XM, Zhang Y, Xu ZQ, et al. Profiles of malignant tumors following kidney transplantation:an analysis of 34 cases[J/CD]. Chin J Transplant:Electr Edit, 2012, 6(2):97-104.
[11]	俞欣, 徐东亮, 柏金明, 等.肾移植术后恶性肿瘤15例临床分析[J].南京医科大学学报:自然科学版, 2010, 30(9):1330-1332. http://www.cnki.com.cn/Article/CJFDTOTAL-NJYK201009033.htm Yu X, Xu DL, Bai JM, et al. Malignant tumors after renal transplantation:an clinical analysis of 15 cases[J]. Acta Univ Med Nanjing:Nat Sci, 2010, 30(9):1330-1332. http://www.cnki.com.cn/Article/CJFDTOTAL-NJYK201009033.htm
[12]	曹文军, 刘致中, 李建新, 等.肾移植术后并发恶性肿瘤11例临床分析[J].中国当代医药, 2012, 19(2):22-24. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201202015.htm Cao WJ, Liu ZZ, Li JX, et al. Clinical analysis of malignant tumors after kidney transplantation[J]. Chin Mod Med, 2012, 19(2):22-24. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201202015.htm
[13]	马永文, 王东文, 石韶华, 等.肾移植术后恶性肿瘤的临床分析[J].实用医技杂志, 2011, 18(8):793-794. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYJ201108004.htm Ma YW, Wang DW, Shi SH, et al. The clinical research of malignant tumor after renal transplantation[J]. J Prac Med Techn, 2011, 18(8):793-794. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYJ201108004.htm
[14]	Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning[J]. Biol Blood Marrow Transplant, 2013, 19(1):117-122. doi: 10.1016/j.bbmt.2012.08.014
[15]	Karczewski M, Czapiewski W, Karczewski J. Urologic de novo malignancies after kidney transplantation:a single center experience[J].Transplant Proc, 2012, 44(5):1293-1297. doi: 10.1016/j.transproceed.2011.11.063
[16]	Cheung CY, Lam MF, Chu KH, et al. Malignancies after kidney transplantation:Hong Kong renal registry[J]. Am J Transplant, 2012, 12(11):3039-3046. doi: 10.1111/j.1600-6143.2012.04209.x
[17]	Elkentaoui H, Robert G, Pasticier G, et al. Therapeutic management of de novo urological malignancy in renal transplant recipients:the experience of the French Department of Urology and Kidney Transplantation from Bordeaux[J]. Urology, 2010, 75(1):126-132. doi: 10.1016/j.urology.2009.06.106
[18]	Andrés A. Cancer incidence after immunosuppressive treatment following kidney transplantation[J]. Crit Rev Oncol Hematol, 2005, 56(1):71-85. doi: 10.1016/j.critrevonc.2004.11.010
[19]	赵平, 程万青. 2009年中国肿瘤登记年报[M].北京:军事医学科学出版社, 2010:42-54, 62-65. Zhao P, Cheng WQ. Chinese cancer registry annual report 2009[M]. Beijing:Military Medical Science Press, 2010:42-54, 62-65.
[20]	彭明强, 杨志豪, 方自林, 等.国内公开报道的肾移植后并发恶性肿瘤病例的总结分析[J].中华器官移植杂志, 2005, 26(5):269-271. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHQG200505003.htm Peng MQ, Yang ZH, Fang ZL, et al. An assemble analysis of malignancy following renal transplantation in China[J]. Chin J Organ Transplant, 2005, 26(5):269-271. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHQG200505003.htm
[21]	Hwang JK, Moon IS, Kim JI. Malignancies after kidney transplantation:a 40-year single-center experience in Korea[J]. Transpl Int, 2011, 24(7):716-721. doi: 10.1111/tri.2011.24.issue-7
[22]	Navarro MD, López-Andréu M, Rodríguez-Benot A, et al. Cancer incidence and survival in kidney transplant patients[J]. Transplant Proc, 2008, 40(9):2936-2940. doi: 10.1016/j.transproceed.2008.09.025
[23]	Puttarajappa C, Yabes J, Bei L, et al. Cancer risk with alemtuzumab following kidney transplantation[J].Clin Transplant, 2013, 27(3):E264-E271. doi: 10.1111/ctr.2013.27.issue-3
[24]	Stratta P, Morellini V, Musetti C, et al. Malignancy after kidney transplantation:results of 400 patients from a single center[J]. Clin Transplant, 2008, 22(4):424-427. doi: 10.1111/ctr.2008.22.issue-4
[25]	Kyllönen L, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population[J]. Transpl Int, 2000, 13(Suppl 1):S394-S398. doi: 10.1007/s001470050369
[26]	Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidney transplantation in the United States[J]. Am J Transplant, 2004, 4(6):905-913. doi: 10.1111/ajt.2004.4.issue-6
[27]	Villeneuve PJ, Schaubel DE, Fenton SS, et al. Cancer incidence among Canadian kidney transplant recipients[J]. Am J Transplant, 2007, 7(4):941-948. doi: 10.1111/ajt.2007.7.issue-4
[28]	Hoshida Y, Tsukuma H, Yasunaga Y, et al. Cancer risk after renal transplantation in Japan[J]. Int J Cancer, 1997, 71(4):517-520. doi: 10.1002/(ISSN)1097-0215
[29]	Shin M, Moon HH, Kim JM, et al. Comparison of the incidence of de novo malignancy in liver or kidney transplant recipients:analysis of 2673 consecutive cases in a single center[J]. Transplant Proc, 2013, 45(8):3019-3023. doi: 10.1016/j.transproceed.2013.08.061
[30]	肖荆.马兜铃酸与肾移植患者术后并发尿路上皮癌关系及Ras、P53基因突变影响的研究[J].现代泌尿外科杂志, 2011, 16(5):480-482. http://www.cnki.com.cn/Article/CJFDTOTAL-MNWK201105040.htm Xiao J. Research on relationship between aristolochic acid and postoperative urothelial carcinoma in renal transplant and the Ras and P53 gene mutation[J]. J Mod Urol, 2011, 16(5):480-482. http://www.cnki.com.cn/Article/CJFDTOTAL-MNWK201105040.htm
[31]	陈瑜, 张雷, 王立明, 等.马兜铃酸肾病患者肾移植术后继发双侧尿路肿瘤一例[J].中华器官移植杂志, 2011, 32(5):271. http://d.wanfangdata.com.cn/Periodical/zhqgyz98201105005 Chen Y, Zhang L, Wang LM, et al. Aristolochic acid nephropathy after renal transplantation in patients with secondary bilateral urinary tract tumors:a report of 1 case[J]. Chin J Organ Transplant, 2011, 32(5):271. http://d.wanfangdata.com.cn/Periodical/zhqgyz98201105005
[32]	杨宏伟, 刘龙.马兜铃酸肾病肾移植术后并发泌尿系肿瘤5例并文献复习[J].现代泌尿生殖肿瘤杂志, 2011, 3(1):45. http://www.cnki.com.cn/Article/CJFDTOTAL-PXDM201101021.htm Yang HW, Liu L. Aristolochic acid nephropathy complicated urinary tumor tract after renal transplantation:a report of 5 cases and literature review[J]. J Contemp Urol Reprod Oncol, 2011, 3(1):45. http://www.cnki.com.cn/Article/CJFDTOTAL-PXDM201101021.htm
[33]	Zustovich F, Ferro A, Toso S. Gemcitabine for the treatment of classic Kaposi's sarcoma:a case series[J]. Anticancer Res, 2013, 33(12):5531-5534. http://cn.bing.com/academic/profile?id=2341146596&encoded=0&v=paper_preview&mkt=zh-cn
[34]	郭继华, 王俊, 孟伟, 等.肾移植后卡波西肉瘤临床病理观察[J].中国癌症杂志, 2006, 16(5):351-353. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ200605006.htm Guo JH, Wang J, Meng W, et al. Clinicopathological changes of renal transplantation related Kaposi's sarcoma[J]. Chin Oncol, 2006, 16(5):351-353. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ200605006.htm